<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00758927</url>
  </required_header>
  <id_info>
    <org_study_id>08-OM-9408</org_study_id>
    <nct_id>NCT00758927</nct_id>
  </id_info>
  <brief_title>The Effects of Omega-3 Fatty Acid (OMACOR) on the Low-density Lipoprotein (LDL) Sub-fraction in Type 2 Diabetic Patients</brief_title>
  <official_title>The Effects of OMACOR on the LDL Sub-fraction in Korean Type 2 Diabetic Patients With Combined Hyperlipidemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inje University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kuhnil Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Inje University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to verify the possible effects of OMACOR(omega-3 fatty acid) on
      the percentage change of small dense LDL fraction in type 2 diabetic patients with combined
      hyperlipidemia, we perform open-label prospective randomized multi-institutional phase IV
      study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main cause of mortality in type 2 diabetes mellitus is a cardiovascular disease. Among
      the many risk factors of atherosclerosis in diabetic patients, LDL(low density lipoprotein)
      cholesterol is now being regarded as one of the most important modifiable one. Recent
      researches have revealed that the plasma LDL could be sub-divided according to the size of
      the particles into large buoyant LDL and small dense LDL. Small dense LDL is very
      atherogenic. Increased plasma triglyceride and the presence of insulin resistance are proved
      to be positively correlated well with the amount of small dense LDL in diabetic patients.

      We would like to see omega-3 acid(OMACOR) which is now widely used in clinical practice to
      decrease plasma triglyceride could change the amount of plasma small dense LDL in type 2
      diabetic patients with combined hyperlipidemia.

      This trial is consisted of 6 weeks of wash out for the patients already taking statin. After
      that, daily 4 grams of omega-3 acid(OMACOR) will be administered for 10 weeks. Before and
      after the administration of study drug, we will measure the change of the amount of plasma
      small dense LDL via ultracentrifuge/non-denaturing polyacrylamide gel electrophoresis
      followed by oil red O and coomassie blue staining. As a secondary outcome measure, we will
      also assess the change of HDL(high density lipoprotein) cholesterol sub-type by the same
      method.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2009</start_date>
  <completion_date type="Anticipated">July 2010</completion_date>
  <primary_completion_date type="Anticipated">April 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage change of plasma small dense LDL measured by ultracentrifuge-non denaturing polyacrylamide gel electrophoresis</measure>
    <time_frame>April 2009</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The percentage change of plasma HDL sub-fraction measured by ultracentrifuge-non denaturing polyacrylamide gel electrophoresis</measure>
    <time_frame>April 2009</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Hypercholesterolemia</condition>
  <condition>Hypertriglyceridemia</condition>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administration for 10 weeks with exercise and diet therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Omacor 4 gram per day with exercise and diet therapy for 10 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omega-3 acid 4 grams per day</intervention_name>
    <description>OMACOR 4 grams per day is administered simultaneously with exercise and diet therapy</description>
    <arm_group_label>1</arm_group_label>
    <other_name>OMACOR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo control</intervention_name>
    <description>Placebo will be administered simultaneously with exercise and diet therapy in same intensity with the experimental arm</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Agreed for informed consent

          -  Age between 40-70 years old

          -  Type 2 diabetes mellitus

          -  Combined hyperlipidemia

          -  Serum triglyceride level between 200-500(mg/dl)

          -  No sudden change of glucose lowering therapies during trial, anticipated

        Exclusion Criteria:

          -  Hypersensitivity to OMACOR(Omega-3 fatty acid)

          -  Alcoholics

          -  Pregnancy

          -  Proliferative diabetic retinopathy

          -  Patients already taking fibrates

          -  Enrolled in other clinical trials during the recent 3 months

          -  Severe ischemic heart disease, liver disease, neurological disease

          -  AST/ALT level 2 folds above the normal reference level

          -  Psychiatric disorder not adequately controlled

          -  Serum creatinine over 2.0 (mg/dl)

          -  Previous pancreatic surgery

          -  Patients who can not maintain regular diet
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeong H Park, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Director, Paik Diabetes Center, Pusan Paik Hospital, Inje University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jeong H Park, M.D., Ph.D.</last_name>
    <phone>82-51-890-6074</phone>
    <email>pjhdoc@chol.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mi K Kim, M.D., Ph.D.</last_name>
    <phone>82-10-4547-9288</phone>
    <email>kmkdoc@hanmail.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dong-A University Medical Center</name>
      <address>
        <city>Busan</city>
        <zip>602-715</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Duk K Kim, M.D., Ph.D.</last_name>
      <phone>82-51-240-5030</phone>
      <email>dkkim@dau.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Paik Diabetes Center</name>
      <address>
        <city>Busan</city>
        <zip>614-735</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeong H Park, M.D., Ph.D.</last_name>
      <phone>82-51-890-6074</phone>
      <email>pjhdoc@chol.com</email>
    </contact>
    <contact_backup>
      <last_name>Sang H Byun, RN, CDE, MS</last_name>
      <phone>82-51-890-6471</phone>
      <email>busanmed260@hanmail.net</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Endocrinology and Metabolism, Maryknoll General Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mikyung Kim, MD PhD</last_name>
      <phone>82-10-4547-9288</phone>
      <email>kmkdoc@yahoo.co.kr</email>
    </contact>
    <investigator>
      <last_name>Mikyung Kim, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 23, 2008</study_first_submitted>
  <study_first_submitted_qc>September 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2008</study_first_posted>
  <last_update_submitted>August 3, 2009</last_update_submitted>
  <last_update_submitted_qc>August 3, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 6, 2009</last_update_posted>
  <responsible_party>
    <name_title>Jeong Hyun Park/Professor</name_title>
    <organization>Pusan Paik Hospital, Inje University</organization>
  </responsible_party>
  <keyword>diabetes mellitus</keyword>
  <keyword>combined hyperlipidemia</keyword>
  <keyword>OMACOR</keyword>
  <keyword>small dense LDL</keyword>
  <keyword>HDL subfraction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hypertriglyceridemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

